Eagle’s Eye View: NOAC vs. Warfarin For AFib, Sex Disparities in Medical-Guided Therapy Among HFrEF Patients, Polygenic Risk in Families With Spontaneous SCAD

Release Date:

In this week’s View, Dr. Eagle discusses the use of non–Vitamin-K antagonist oral anticoagulants versus warfarin across the spectrum of body mass index and weight. He then explores sex disparities in longitudinal use and intensification of guideline-directed medical therapy among patients with newly diagnosed heart failure with reduced ejection fraction. Finally, Dr. Eagle talks about polygenic risk in families with spontaneous coronary artery dissection.  Subscribe to Eagle’s Eye View  

Eagle’s Eye View: NOAC vs. Warfarin For AFib, Sex Disparities in Medical-Guided Therapy Among HFrEF Patients, Polygenic Risk in Families With Spontaneous SCAD

Title
Eagle’s Eye View: NOAC vs. Warfarin For AFib, Sex Disparities in Medical-Guided Therapy Among HFrEF Patients, Polygenic Risk in Families With Spontaneous SCAD
Copyright
Release Date

flashback